186 related articles for article (PubMed ID: 35927957)
21. Clot penetration and retention by plasminogen activators promote fibrinolysis.
Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
[TBL] [Abstract][Full Text] [Related]
22. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms.
Fay WP; Eitzman DT; Shapiro AD; Madison EL; Ginsburg D
Blood; 1994 Jan; 83(2):351-6. PubMed ID: 8286735
[TBL] [Abstract][Full Text] [Related]
23. Fibrin clots obtained from plasma containing heparin show a higher sensitivity to t-PA-induced lysis.
Nenci GG; Parise P; Morini M; Rossini A; Agnelli G
Blood Coagul Fibrinolysis; 1992 Jun; 3(3):279-85. PubMed ID: 1643205
[TBL] [Abstract][Full Text] [Related]
24. Internal fibrinolysis of fibrin clots is driven by pore expansion.
Risman RA; Paynter B; Percoco V; Shroff M; Bannish BE; Tutwiler V
Sci Rep; 2024 Feb; 14(1):2623. PubMed ID: 38297113
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms of the effect of ultrasound on the fibrinolysis of clots.
Chernysh IN; Everbach CE; Purohit PK; Weisel JW
J Thromb Haemost; 2015 Apr; 13(4):601-9. PubMed ID: 25619618
[TBL] [Abstract][Full Text] [Related]
26. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
[TBL] [Abstract][Full Text] [Related]
27. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface.
Braaten JV; Jerome WG; Hantgan RR
Blood; 1994 Feb; 83(4):982-93. PubMed ID: 8111066
[TBL] [Abstract][Full Text] [Related]
28. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
29. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
30. Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation.
Duboscq C; Genoud V; Parborell MF; Kordich LC
Thromb Res; 1997 Jun; 86(6):505-13. PubMed ID: 9219330
[TBL] [Abstract][Full Text] [Related]
31. Probing interactions of red blood cells and contracting fibrin platelet clots.
Sun Y; Le H; Lam WA; Alexeev A
Biophys J; 2023 Nov; 122(21):4123-4134. PubMed ID: 37598293
[TBL] [Abstract][Full Text] [Related]
32. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.
Torr-Brown SR; Sobel BE
Thromb Res; 1993 Dec; 72(5):413-21. PubMed ID: 8303684
[TBL] [Abstract][Full Text] [Related]
33. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
34. [Plasminogen activation by tissue plasminogen activator on fibrin clots with different surface structures].
Savchuk AN
Ukr Biokhim Zh (1999); 2001; 73(3):87-90. PubMed ID: 12035559
[TBL] [Abstract][Full Text] [Related]
35. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
36. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
37. The role of platelets and leukocytes in coagulation and fibrinolysis.
Cucuianu M; Trif I
Rev Roum Physiol (1990); 1992; 29(1-2):33-8. PubMed ID: 1472550
[TBL] [Abstract][Full Text] [Related]
38. Clot uptake of labeled active and inhibited tissue plasminogen activator.
Lavie E; Bitton M; Shalev J; Weininger J; Abrashkin S; Varga E; Lubin E; Azoury R
Biochim Biophys Acta; 1989 Apr; 991(1):62-7. PubMed ID: 2496763
[TBL] [Abstract][Full Text] [Related]
39. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
40. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
